Novo Nordisk (NYSE: NVO) has come under pressure over the past year (down almost 52%) as profit assumptions for its weight loss drug Wegovy have been pared back. A combination of high-profile quality control issues, supply chain bottlenecks , and increasing competition from Eli Lilly‘s (NYSE: LLY) Zepbound have dramatically reset investor expectations.
Still, the company looks set to turn the tide in the battle over weight loss drugs. Here’s why.
Image source: Getty Images.